PHARMACIE ZERROUKI-RAMDANI : revenue, balance sheet and financial ratios

PHARMACIE ZERROUKI-RAMDANI is a French company founded 14 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in ROUBAIX (59100), this company of category PME shows in 2017 a revenue of 1.8 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-18

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - PHARMACIE ZERROUKI-RAMDANI (SIREN 532664877)
Indicator 2024 2023 2022 2019 2018 2017 2016
Revenue N/C N/C N/C N/C N/C 1 802 873 € 1 747 778 €
Net income 2 789 € 43 741 € 176 748 € 102 268 € 229 752 € 121 830 € 76 739 €
EBITDA N/C N/C N/C N/C N/C 313 530 € 176 533 €
Net margin N/C N/C N/C N/C N/C 6.8% 4.4%

Revenue and income statement

In 2024, PHARMACIE ZERROUKI-RAMDANI generates positive net income of 3 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 77 k€ -> 3 k€.

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

2 789 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 26%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 63%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

26.419%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

62.696%

Asset age ratio (2024) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

17.9%

Solvency indicators evolution
PHARMACIE ZERROUKI-RAMDANI

Sector positioning

Debt ratio
26.42 2024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Good

In 2024, the debt ratio of PHARMACIE ZERROUKI-RAMDANI (26.42) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
62.7% 2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Good +10 pts over 3 years

In 2024, the financial autonomy of PHARMACIE ZERROUKI-RAMDANI (62.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 53.74. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

53.742

Liquidity indicators evolution
PHARMACIE ZERROUKI-RAMDANI

Sector positioning

Liquidity ratio
53.74 2024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Watch

In 2024, the liquidity ratio of PHARMACIE ZERROUKI-RAMDANI (53.74) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 59 days. Excellent situation: suppliers finance 59 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

59 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
PHARMACIE ZERROUKI-RAMDANI

Positioning of PHARMACIE ZERROUKI-RAMDANI in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 225 transactions of similar company sales in 2024, the value of PHARMACIE ZERROUKI-RAMDANI is estimated at 38 936 € (range 27 114€ - 58 251€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2024
225 transactions
27k€ 38k€ 58k€
38 936 € Range: 27 114€ - 58 251€
NAF 5 année 2024

Valuation method used

Net Income Multiple
2 789 € × 14.0x = 38 937 €
Range: 27 115€ - 58 251€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare PHARMACIE ZERROUKI-RAMDANI with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about PHARMACIE ZERROUKI-RAMDANI

What is the revenue of PHARMACIE ZERROUKI-RAMDANI ?

The revenue of PHARMACIE ZERROUKI-RAMDANI in 2017 is 1.8 M€.

Is PHARMACIE ZERROUKI-RAMDANI profitable?

Yes, PHARMACIE ZERROUKI-RAMDANI generated a net profit of 3 k€ in 2024.

Where is the headquarters of PHARMACIE ZERROUKI-RAMDANI ?

The headquarters of PHARMACIE ZERROUKI-RAMDANI is located in ROUBAIX (59100), in the department Nord.

Where to find the tax return of PHARMACIE ZERROUKI-RAMDANI ?

The tax return of PHARMACIE ZERROUKI-RAMDANI is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does PHARMACIE ZERROUKI-RAMDANI operate?

PHARMACIE ZERROUKI-RAMDANI operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.